Rafarma Pharmaceuticals constructed and now operates a 270,000-square foot multi-purpose pharmaceutical facility in Russia in direct response to the Russian Government's plan to significantly advance the domestic pharmaceutical industry in the Russian Federation.
In a recent video interview with the QualityStocks Production team, Rafarma CEO Sergey Brunsnitsyn details the operations and qualification of the production plant, how it meets world standards in the field of pharmaceuticals and industrial construction, and the company's strategy to secure 5 percent of market share in the Russian pharmaceuticals market by 2017.
"The strategies of the company, the professional team, the modern production facilities and our projects allow us to look forward with confidence and ensure the presence of high-quality generics and innovative medical products for our Russian and foreign consumers," Brunsnitsyn says in the interview.
To view the entire video production visit videos.qualitystocks.net
For more information visit rafarma.com
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net